Monday, November 9, 2026

ZoomInfo And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

August 25, 2021

ZoomInfo  And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

(VIANEWS) - ZoomInfo (ZI), Coastal Financial Corporation (CCB), Eli Lilly and Company (LLY) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. ZoomInfo (ZI)

48.3% sales growth and 4.28% return on equity

ZoomInfo Technologies Inc. operates cloud-based go-to-market intelligence platform for sales and marketing teams in the United States and internationally.

ZoomInfo's sales growth this year is expected to be 48.2% and 31.2% for next year.

Year-on-year quarterly revenue growth grew by 56.9%, now sitting on 590.4M for the twelve trailing months.

Volume

Today's last reported volume for ZoomInfo is 1803140 which is 40.77% below its average volume of 3044440.

ZoomInfo's sales growth for the next quarter is 48.3%. The company's growth estimates for the present quarter and the next is 71.4% and 9.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.28%.

Volatility

ZoomInfo's last day, last week, and last month's current volatility was 2.55%, 1.26%, and 2.64%, respectively.

ZoomInfo's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.77% (day), 3.66% (last week), and 5.03% (last month), respectively.

ZoomInfo's Stock Yearly Top and Bottom Value

ZoomInfo's stock is valued at $61.17 at 06:22 EST, below its 52-week high of $67.63 and way above its 52-week low of $30.83.

ZoomInfo's Moving Average

ZoomInfo's value is higher than its 50-day moving average of $56.30 and way higher than its 200-day moving average of $50.81.

2. Coastal Financial Corporation (CCB)

21.8% sales growth and 15.28% return on equity

Coastal Financial Corporation operates as the bank holding company for Coastal Community Bank that provides various banking products and services to small to medium-sized businesses, professionals, and individuals in the Puget Sound region in Washington.

Coastal Financial Corporation's sales growth this year is expected to be 33.3% and 10.4% for next year.

Year-on-year quarterly revenue growth grew by 69.7%, now sitting on 74.07M for the twelve trailing months.

Volume

Today's last reported volume for Coastal Financial Corporation is 12079 which is 59.42% below its average volume of 29767.

Coastal Financial Corporation's sales growth for the next quarter is 21.8%. The company's growth estimates for the current quarter and the next is 26.5% and 31.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.28%.

Volatility

Coastal Financial Corporation's last day, last week, and last month's current volatility was 0.37%, 0.80%, and 1.33%, respectively.

Coastal Financial Corporation's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.25% (day), 4.01% (last week), and 4.07% (last month), respectively.

Coastal Financial Corporation's Stock Yearly Top and Bottom Value

Coastal Financial Corporation's stock is valued at $29.60 at 06:22 EST, way under its 52-week high of $33.76 and way above its 52-week low of $11.58.

Coastal Financial Corporation's Moving Average

Coastal Financial Corporation's worth is above its 50-day moving average of $29.40 and higher than its 200-day moving average of $28.49.

3. Eli Lilly and Company (LLY)

14.6% sales growth and 111.03% return on equity

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide.

Eli Lilly and Company's sales growth this year is expected to be 10.7% and 1.9% for next year.

Year-on-year quarterly revenue growth grew by 22.6%, now sitting on 26.73B for the twelve trailing months.

Volume

Today's last reported volume for Eli Lilly and Company is 3197160 which is 0.51% below its average volume of 3213870.

Eli Lilly and Company's sales growth for the next quarter is 14.6%. The company's growth estimates for the current quarter and the next is a negative 0% and 27.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 111.03%.

Volatility

Eli Lilly and Company's last day, last week, and last month's current volatility was 1.15%, 0.93%, and 1.10%, respectively.

Eli Lilly and Company's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.95% (day), 2.31% (last week), and 2.34% (last month), respectively.

Eli Lilly and Company's Stock Yearly Top and Bottom Value

Eli Lilly and Company's stock is valued at $262.77 at 06:22 EST, under its 52-week high of $275.87 and way above its 52-week low of $129.21.

Eli Lilly and Company's Moving Average

Eli Lilly and Company's value is above its 50-day moving average of $250.50 and way higher than its 200-day moving average of $213.08.

4. Stepan Company (SCL)

9.5% sales growth and 15.21% return on equity

Stepan Company, together with its subsidiaries, produces and sells specialty and intermediate chemicals to other manufacturers for use in various end products in North America, Europe, Latin America, and Asia.

Stepan Company's sales growth this year is expected to be 19.3% and 2.9% for next year.

Year-on-year quarterly revenue growth grew by 29.3%, now sitting on 2.09B for the twelve trailing months.

Volume

Today's last reported volume for Stepan Company is 55542 which is 22.39% below its average volume of 71573.

Stepan Company's sales growth is a negative 0% for the current quarter and 9.5% for the next. The company's growth estimates for the ongoing quarter and the next is 5.8% and negative -0.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.21%.

Volatility

Stepan Company's last day, last week, and last month's current volatility was 1.84%, 1.04%, and 0.94%, respectively.

Stepan Company's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.07% (day), 1.57% (last week), and 1.79% (last month), respectively.

Stepan Company's Stock Yearly Top and Bottom Value

Stepan Company's stock is valued at $115.49 at 06:22 EST, way below its 52-week high of $139.30 and above its 52-week low of $105.96.

Stepan Company's Moving Average

Stepan Company's worth is under its 50-day moving average of $117.52 and under its 200-day moving average of $125.83.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,558 source documents archived
Query this data → isubstrate.com